Additionally, it is not possible to say with absolute certainty if the detected coldspot mutation of the BRCA2 gene in the locally recurrent tumor of the young patient with proven BRCA2 methylation, from where the organoids were created led to an additional susceptibility to PARP inhibitors, even though structural analysis suggest that it does not disrupt the function of the BRCA2 protein and should thus not lead to a HRD. The gene discussed is BRCA2; the disease is neoplasm.